Vaniqa - the new topical treatment that slows the growth of unwanted facial
hair in women
To view the Social Media Release, click here: http://smr.newswire.ca/en/triton-pharma/launch-of-vaniqa
TORONTO, July 19 /CNW/ - Triton Pharma Inc. announces the launch of VANIQA(R), the only topical prescription treatment cream that slows the growth of facial hair in women.
About VANIQA(R) (eflornithine hydrochloride 13.9%)
Women with unwanted facial hair spend on average 104 minutes weekly on hair removal. Finally, a new way to help manage this condition is available in Canada.
VANIQA(R) (Eflornithine 13.9% hydrochloride) cream, applied twice-daily on affected area, can help women by slowing the growth of their unwanted facial hair.
VANIQA(R) is the first prescription cream clinically proven to slow the growth of unwanted facial hair in women. It is not a hair remover, but complements any hair removal technique. VANIQA(R) Cream can easily be integrated in your daily make-up routine. By its innovative mechanism of action, VANIQA(R) cream interferes with a natural component of the skin needed for hair growth. This results in slower hair growth and improved appearance where VANIQA(R) is applied.
About Unwanted Facial Hair
Unwanted facial hair, or hirsutism, can affect women of all ages, skin types or hair colour and can be a source of considerable emotional distress and social embarrassment. Hirsutism can have a detrimental impact on a woman's body image and quality of life, as it contradicts cultural and social perceptions of what is physically attractive or acceptable.
Current depilatory methods require repeated treatments and may be uncomfortable or costly. VANIQA(R) has been clinically proven to reduce the growth of facial hair, whichever hair removal method is used, in whichever hair colour or whichever skin type. VANIQA(R) has been shown to complement laser therapy in particular by producing a synergistic effect, leading to faster and better end results for the patient.
About Triton Pharma Inc.
Triton Pharma markets products with the potential to significantly improve women and men's health with products for menopause, dermatology and urology.
Women who are interested in learning more about VANIQA(R) should ask their doctor or a dermatologist or visit www.tritonpharma.ca
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available at http://photos.newswire.ca. Images are free to accredited members of the media/
For further information: Women who are interested in learning more about VANIQA(R) should ask their doctor or a dermatologist or visit www.tritonpharma.ca; Media Contact: Liu Dambolena, [email protected]
Share this article